[{"NetIncomeLoss_1_Q1_USD":5761600.0,"AssetsCurrent_0_Q1_USD":2986107.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q1_USD":1421817.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":1656000000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":-1725000000.0,"CommitmentsAndContingencies_0_Q1_USD":null,"GeneralAndAdministrativeExpense_1_Q1_USD":295117.0,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"Liabilities_0_Q1_USD":150139317.0,"Cash_0_Q1_USD":1917469.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q1_USD":1572791350.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":1917469.0,"FairValueAdjustmentOfWarrants_1_Q1_USD":-9532500.0,"PaymentsOfStockIssuanceCosts_1_Q1_USD":155760.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":1727387907.0,"ProceedsFromIssuanceOfPrivatePlacement_1_Q1_USD":28875000.0,"AssetsHeldInTrustNoncurrent_0_Q1_USD":1725044564.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":893317.0,"WarrantsAndRightsOutstanding_0_Q1_USD":88342500.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0_Q1_USD":0.0,"IncomeTaxExpenseBenefit_1_Q1_USD":0.0,"IncomeLossFromContinuingOperations_1_Q1_USD":5717036.0,"AssetsHeldInTrust_0_Q1_USD":1917469.0,"UnrecognizedTaxBenefits_0_Q1_USD":0.0,"CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1_Q1_USD":1917469.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"CashEquivalentsAtCarryingValue_0_Q1_USD":0.0,"AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1_Q1_USD":83990246.0,"LiabilitiesCurrent_0_Q1_USD":1421817.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-470438.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":5761600.0,"PaymentsToAcquireRestrictedInvestments_1_Q1_USD":1725000000.0,"PaymentsForUnderwritingExpense_1_Q1_USD":25875000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":4994170.0,"StockholdersEquity_0_Q1_USD":5000004.0,"CashFDICInsuredAmount_0_Q1_USD":250000.0,"SharePrice_0_Q1_USD":10.0,"GainLossOnSaleOfDerivatives_1_Q1_USD":9817500.0,"PreferredStockSharesAuthorized_0_Q1_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":1728030671.0,"PreferredStockValue_0_Q1_USD":0.0,"ProceedsFromIssuanceInitialPublicOffering_1_Q1_USD":1725000000.0,"OperatingIncomeLoss_1_Q1_USD":-295117.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.0001,"StockRedeemedOrCalledDuringPeriodValue_1_Q1_USD":-1572791350.0,"Assets_0_Q1_USD":1728030671.0,"PrepaidExpenseCurrent_0_Q1_USD":1068638.0,"IncreaseDecreaseInPrepaidExpense_1_Q1_USD":1068638.0,"Ticker":"DNA","CIK":"1830214","name":"SOARING EAGLE ACQUISITION CORP.","OfficialName":"Ginkgo Bioworks Holdings Inc. Class A Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"6721688334.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NYSE","SP500":"nan","filed":"20210524"}]